Anna Galkin

Anna Galkin

Company: Axelia Oncology

Job title: CSO


Developing a Systemically Delivered TLR2 Agonist for Cancer Immunotherapy 3:30 pm

Understand the mechanistic rationale for pursuing TLR2 agonists in CPI resistant solid tumor indications Review the safety and tolerability profile of AXA-042 demonstrated in the first-in-human clinical trial Translational lessons from the clinic: impact of TLR2 target engagement on clinical safety and response biomarkers Read more

day: Conference Day 2

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.